LIPO Overview

Event Announcement: The Life Science Virtual Investor Forum is scheduled for September 18, 2025, co-hosted by Zacks SCR, inviting individual and institutional investors to attend presentations and one-on-one meetings with company management.

Participation Details: Investors are encouraged to pre-register and perform an online system check for a smoother experience, with no cost to attend live presentations or schedule meetings.

U.S. Stock Market Performance: U.S. stocks showed mixed results with the Nasdaq Composite gaining over 50 points, while the S&P Global US services PMI fell to 53.1 in June, slightly above market expectations.

Sector Movements and Notable Stocks: Consumer discretionary shares rose by 1.6%, while health care stocks declined. Significant stock movements included Impact BioMedical's shares surging 386% due to a merger announcement, and Hims & Hers Health's shares dropping 28% after a collaboration termination.

U.S. Stock Market Performance: U.S. stocks opened higher with the Dow Jones gaining over 200 points, driven by a rise in consumer discretionary shares and notable gains from companies like FactSet Research Systems and Impact BioMedical Inc.

Global Market Trends: European shares mostly declined, while Asian markets showed mixed results; additionally, U.S. service PMI fell slightly, indicating a modest slowdown in economic activity.

Patent Issuance: Lipella Pharmaceuticals has received U.S. Patent No. 12,326,492 for a novel MRI method to detect interstitial cystitis, enhancing their development programs for mucosal disorders and providing protection until at least 2045.

Clinical Implications: The non-invasive detection method is expected to improve clinical outcomes and serve as an early detection tool for related bladder diseases, supporting Lipella's focus on addressing significant unmet medical needs.

Collaboration Renewal: Lipella Pharmaceuticals has renewed its manufacturing collaboration agreement with Cook MyoSite to support the Chemistry, Manufacturing and Control (CMC) documentation for its clinical products LP-10 and LP-310.

Company Focus: Lipella is a clinical-stage biotechnology company aiming to develop therapies for diseases with significant unmet needs by reformulating existing generic drugs, having completed its IPO in 2022.

Presentation of Phase 2a Trial Data: Lipella Pharmaceuticals will present topline data from its Phase 2a trial of LP-310, a liposomal tacrolimus oral rinse for Oral Lichen Planus, on May 15, 2025, showing significant safety and efficacy results from the 0.50 mg dose cohort.

Positive Treatment Outcomes: The treatment demonstrated statistically significant improvements in pain and inflammation, with no serious adverse events reported, indicating LP-310's potential as a localized, non-steroidal therapy for Oral Lichen Planus.